RAF1 and melanoma: Moreover, belvarefenib, a selective RAF dimer inhibitor, in combination with cobimetinib demonstrated some efficacy in NRAS mutant melanoma treated with prior ICI therapy in a phase Ib study (NCT03284502) [68] and it is currently in evaluation as a single agent or in combination with cobimetinib or with cobimetinib plus atezolizumab in 83 patients with NRAS-mutant advanced melanoma who were previously treated with anti-PD-1/PD-L1 therapy (NCT04835805).